Is UnitedHealth stock a Buy, Sell or Hold?
UnitedHealth stock has received a consensus rating of buy. The average rating score is A3 and is based on 61 buy ratings, 9 hold ratings, and 0 sell ratings.What was the 52-week low for UnitedHealth stock?
The low in the last 52 weeks of UnitedHealth stock was 449.90. According to the current price, UnitedHealth is 104.36% away from the 52-week low.What was the 52-week high for UnitedHealth stock?
The high in the last 52 weeks of UnitedHealth stock was 558.10. According to the current price, UnitedHealth is 84.12% away from the 52-week high.What are analysts forecasts for UnitedHealth stock?
The 70 analysts offering price forecasts for UnitedHealth have a median target of 538.51, with a high estimate of 650.00 and a low estimate of 394.00. The median estimate represents a 87.18 difference from the last price of 469.50.UnitedHealth Stock Snapshot
469.50
Bid
7,800.00
Bid Size
469.51
Ask
8,200.00
Ask Size
3/17/2023
Date
4:15 PM
Time
2.77 M
Volume
472.02
Prev. Close
471.39
Open
434.38 B
Market Cap
932.85 M
Number of Shares
466.31
Day Low
472.01
Day High
469.50
449.90
52 Week Low
558.10
52 Week High
469.50
6.96
Dividend
1.50
Dividend Yield
23.83
P/E Ratio
99.56
Free Float in %
24.93
EPS 2023
97.46
Book Value per Share
31.62
Cash Flow per Share
UnitedHealth News More News
UnitedHealth Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
UnitedHealth Analyst Data
Total Analysts: 70
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 394.00
Median: 538.51
Highest: 650.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
UnitedHealth Analyst Opinions
- All
- Buy
- Hold
- Sell
| 02/28/23 | Stephens Inc. | Maintained Buy | $605 | ||
| 01/24/23 | Deutsche Bank | Maintained Buy | $617 | ||
| 01/18/23 | UBS | Maintained Hold | $550 | ||
| 01/17/23 | SVB Leerink | Maintained Buy | $625 | ||
| 12/07/22 | Credit Suisse | Maintained Buy | $610 | ||
| 11/23/22 | Morgan Stanley | Maintained Buy | $587 | ||
| 11/21/22 | Raymond James Financial, Inc. | Downgraded to Buy | $615 | ||
| 10/19/22 | Raymond James Financial, Inc. | Maintained Buy | $615 | ||
| 10/18/22 | Deutsche Bank | Maintained Buy | $615 | ||
| 10/17/22 | RBC Capital Markets | Maintained Buy | $592 | ||
| 10/17/22 | Credit Suisse | Maintained Buy | $590 | ||
| 10/17/22 | SVB Leerink | Maintained Buy | $618 | ||
| 09/22/22 | Raymond James Financial, Inc. | Maintained Buy | $635 | ||
| 09/08/22 | Deutsche Bank | Maintained Buy | $569 | ||
| 08/10/22 | Mizuho | Maintained Buy | $600 | ||
| 07/25/22 | Argus Research Company | Maintained Buy | $650 | ||
| 07/21/22 | UBS | Maintained Hold | $570 | ||
| 07/19/22 | Deutsche Bank | Maintained Buy | $556 | ||
| 07/18/22 | Oppenheimer & Co. Inc. | Maintained Buy | $610 | ||
| 07/18/22 | SVB Leerink | Maintained Buy | $625 | ||
| 07/18/22 | Morgan Stanley | Maintained Buy | $587 | ||
| 07/18/22 | Credit Suisse | Maintained Buy | $579 | ||
| 07/14/22 | Morgan Stanley | Maintained Buy | $570 | ||
| 06/17/22 | Loop Capital | Maintained Buy | $575 | ||
| 05/27/22 | Bernstein | Downgraded to Hold | $561 | ||
| 05/25/22 | Wells Fargo & Co | Maintained Buy | $612 | ||
| 04/22/22 | Wells Fargo & Co | Maintained Buy | $613 | ||
| 04/19/22 | BMO Capital Markets | Maintained Buy | $600 | ||
| 04/19/22 | Raymond James Financial, Inc. | Maintained Buy | $620 | ||
| 04/19/22 | SVB Leerink | Maintained Buy | $600 | ||
| 04/18/22 | Oppenheimer & Co. Inc. | Maintained Buy | $600 | ||
| 04/18/22 | Morgan Stanley | Maintained Buy | $577 | ||
| 04/18/22 | Deutsche Bank | Maintained Buy | $549 | ||
| 04/18/22 | RBC Capital Markets | Maintained Buy | $588 | ||
| 04/18/22 | Credit Suisse | Maintained Buy | $595 | ||
| 03/30/22 | Barclays Capital | Maintained Buy | $565 | ||
| 01/26/22 | SVB Leerink | Maintained Buy | $550 | ||
| 01/21/22 | BMO Capital Markets | Maintained Buy | $510 | ||
| 01/21/22 | Raymond James Financial, Inc. | Maintained Buy | $540 | ||
| 01/20/22 | Deutsche Bank | Maintained Buy | $482 | ||
| 12/20/21 | Mizuho | Maintained Buy | $550 | ||
| 12/14/21 | Goldman Sachs | Maintained Buy | $535 | ||
| 12/02/21 | BMO Capital Markets | Maintained Buy | $500 | ||
| 12/01/21 | UBS | Maintained Hold | $452 | ||
| 12/01/21 | Morgan Stanley | Maintained Buy | $526 | ||
| 11/10/21 | Mizuho | Maintained Buy | $500 | ||
| 10/25/21 | Wells Fargo & Co | Maintained Buy | $520 | ||
| 10/15/21 | Morgan Stanley | Maintained Buy | $499 | ||
| 10/15/21 | Oppenheimer & Co. Inc. | Maintained Buy | $475 | ||
| 10/15/21 | Credit Suisse | Maintained Buy | $495 |
UnitedHealth Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
| Revenue | 359,795 | 386,713 | 421,869 | 476,818 | 529,858 |
| Dividend | 6.96 | 7.62 | 8.23 | - | - |
| Dividend Yield (in %) | 1.50 % | 1.64 % | 1.77 % | - | - |
| EPS | 24.93 | 28.29 | 32.34 | 37.76 | 42.35 |
| P/E Ratio | 19.09 | 16.82 | 14.71 | 12.60 | 11.23 |
| EBIT | 31,881 | 35,660 | 40,163 | 46,141 | 49,470 |
| EBITDA | 35,794 | 39,791 | 44,628 | 48,262 | 52,890 |
| Net Profit | 22,471 | 25,359 | 28,981 | 32,824 | 35,458 |
| Net Profit Adjusted | 22,982 | 25,774 | 28,688 | 33,534 | - |
| Pre-Tax Profit | 29,221 | 33,034 | 37,459 | 42,668 | 46,064 |
| Net Profit (Adjusted) | 28,805 | 32,434 | 35,331 | - | - |
| EPS (Non-GAAP) ex. SOE | 24.00 | 27.63 | 31.60 | 38.02 | 43.14 |
| EPS (GAAP) | 23.68 | 26.98 | 31.20 | 36.78 | 41.81 |
| Gross Income | 90,219 | 97,932 | 107,922 | - | - |
| Cash Flow from Investing | -9,241 | -8,629 | -12,695 | -18,782 | -22,450 |
| Cash Flow from Operations | 27,243 | 31,279 | 36,483 | 41,735 | 40,730 |
| Cash Flow from Financing | -14,656 | -17,553 | -18,318 | -16,848 | -22,821 |
| Cash Flow per Share | 31.62 | 33.08 | 38.51 | - | - |
| Free Cash Flow | 24,477 | 27,330 | 29,025 | 31,978 | 35,270 |
| Free Cash Flow per Share | 27.31 | - | - | - | - |
| Book Value per Share | 97.46 | 110.22 | 125.81 | - | - |
| Net Debt | 18,483 | 8,164 | -6,762 | -10,207 | - |
| Research & Development Exp. | - | - | - | - | - |
| Capital Expenditure | 3,220 | 3,390 | 3,501 | 3,804 | 4,681 |
| Selling, General & Admin. Exp. | 53,877 | 57,336 | 60,826 | - | - |
| Shareholder’s Equity | 91,220 | 100,147 | 109,217 | 127,381 | 131,156 |
| Total Assets | 259,831 | 273,116 | 290,794 | 322,306 | 295,411 |
|
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 23 | 21 | 21 | 24 | 23 |
| Average Estimate | 5.173 USD | 6.167 USD | 6.266 USD | 24.928 USD | 28.293 USD |
| Year Ago | 4.480 USD | 5.490 USD | 5.570 USD | 22.190 USD | 24.928 USD |
| Publish Date | 1/13/2023 | 4/18/2023 | 7/18/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 18 | 17 | 17 | 19 | 17 |
| Average Estimate | 82,484 USD | 89,712 USD | 89,683 USD | 359,795 USD | 386,713 USD |
| Year Ago | 73,743 USD | 80,149 USD | 80,332 USD | 324,162 USD | 359,795 USD |
| Publish Date | 1/13/2023 | 4/18/2023 | 7/18/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
UnitedHealth Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| WITTY ANDREW | 02/23/2023 | 1,156.00 | 92,641.09 | 484.33 | Sell | No |
| McMahon Dirk C | 02/23/2023 | 600.25 | 63,535.51 | 484.33 | Sell | No |
| REX JOHN F | 02/23/2023 | 791.45 | 153,297.65 | 484.33 | Sell | No |
| THOMPSON BRIAN R | 02/23/2023 | 460.13 | 32,609.79 | 484.33 | Sell | No |
| McSweeney Erin | 02/23/2023 | 397.06 | 9,838.27 | 484.33 | Sell | No |
| ROOS THOMAS E | 02/23/2023 | 422.33 | 34,284.56 | 484.33 | Sell | No |
| HEMSLEY STEPHEN J | 02/23/2023 | 999.09 | 412,551.58 | 484.33 | Sell | No |
| WITTY ANDREW | 02/22/2023 | 9,994.51 | 83,627.09 | 491.69 | Sell | No |
| McMahon Dirk C | 02/22/2023 | 7,944.89 | 57,321.75 | 491.69 | Sell | No |
| REX JOHN F | 02/22/2023 | 8,572.12 | 147,275.09 | 491.69 | Sell | No |
| THOMPSON BRIAN R | 02/22/2023 | 4,414.08 | 29,001.92 | 491.69 | Sell | No |
| Bondy Rupert M | 02/22/2023 | 1,351.05 | 3,951.75 | 491.69 | Sell | No |
| WITTY ANDREW | 02/22/2023 | 10,170.00 | 93,797.09 | 491.69 | Buy | No |
| WITTY ANDREW | 02/22/2023 | 20,714.00 | 93,621.59 | 491.69 | Buy | No |
| McMahon Dirk C | 02/22/2023 | 6,814.00 | 64,135.75 | 491.69 | Buy | No |
| McMahon Dirk C | 02/22/2023 | 17,423.00 | 65,266.64 | 491.69 | Buy | No |
| REX JOHN F | 02/22/2023 | 6,814.00 | 154,089.09 | 491.69 | Buy | No |
| REX JOHN F | 02/22/2023 | 17,423.00 | 155,847.21 | 491.69 | Buy | No |
| THOMPSON BRIAN R | 02/22/2023 | 4,068.00 | 33,069.92 | 491.69 | Buy | No |
| THOMPSON BRIAN R | 02/22/2023 | 9,680.00 | 33,416.00 | 491.69 | Buy | No |
| Bondy Rupert M | 02/22/2023 | 2,289.00 | 6,240.75 | 491.69 | Buy | No |
| Bondy Rupert M | 02/22/2023 | 2,985.00 | 5,302.81 | 491.69 | Buy | No |
| McSweeney Erin | 02/22/2023 | 2,034.00 | 10,235.33 | 491.69 | Buy | No |
| ROOS THOMAS E | 02/22/2023 | 1,170.00 | 34,706.89 | 491.69 | Buy | No |
| McSweeney Erin | 02/21/2023 | 213.17 | 10,381.12 | 488.89 | Sell | No |
UnitedHealth Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | UnitedHealth Inc. | 6.40 | 1.21 | USD |
| 2021 | UnitedHealth Inc. | 5.60 | 1.12 | USD |
| 2020 | UnitedHealth Inc. | 4.83 | 1.38 | USD |
| 2019 | UnitedHealth Inc. | 4.14 | 1.41 | USD |
| 2018 | UnitedHealth Inc. | 3.45 | 1.38 | USD |
| 2017 | UnitedHealth Inc. | 2.88 | 1.30 | USD |
| 2016 | UnitedHealth Inc. | 2.38 | 1.48 | USD |
| 2015 | UnitedHealth Inc. | 1.88 | 1.59 | USD |
| 2014 | UnitedHealth Inc. | 1.41 | 1.39 | USD |
| 2013 | UnitedHealth Inc. | 1.05 | 1.40 | USD |
| 2012 | UnitedHealth Inc. | 0.80 | 1.47 | USD |
| 2011 | UnitedHealth Inc. | 0.61 | 1.21 | USD |
| 2010 | UnitedHealth Inc. | 0.41 | 1.12 | USD |
| 2009 | UnitedHealth Inc. | 0.03 | 0.10 | USD |
| 2008 | UnitedHealth Inc. | 0.03 | 0.11 | USD |
| 2007 | UnitedHealth Inc. | 0.03 | 0.05 | USD |
| 2006 | UnitedHealth Inc. | 0.03 | 0.06 | USD |
| 2005 | UnitedHealth Inc. | 0.02 | 0.03 | USD |
| 2004 | UnitedHealth Inc. | 0.02 | 0.05 | USD |
| 2003 | UnitedHealth Inc. | 0.01 | 0.03 | USD |
| 2002 | UnitedHealth Inc. | 0.01 | 0.05 | USD |
| 2001 | UnitedHealth Inc. | 0.01 | 0.06 | USD |
| 2000 | UnitedHealth Inc. | 0.01 | 0.07 | USD |
| 1999 | UnitedHealth Inc. | 0.01 | 0.15 | USD |
*Yield of the Respective Date
UnitedHealth Inc. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 6.167 USD | Q1 2023 Earnings Release | 04/18/2023 |
| Earnings Report | 6.266 USD | Q2 2023 Earnings Release | 07/18/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 10/17/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 01/16/2024 |
UnitedHealth Inc. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Press Conference | - | - | 01/13/2023 |
| Earnings Report | 5.340 USD | Q4 2022 Earnings Release | 01/13/2023 |
| Press Conference | - | - | 07/15/2022 |
| Shareholders' Meeting | - | - | 06/06/2022 |
UnitedHealth Profile
UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T.
Moody’s Daily Credit Risk Score
UnitedHealth Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.56 |
| Vanguard Group, Inc. (Subfiler) | 8.59 |
| State Street Corp. | 4.95 |
| Fidelity Management & Research Co. LLC | 4.17 |
| T. Rowe Price Associates, Inc. (Investment Management) | 3.43 |
| Capital Research & Management Co. (World Investors) | 3.29 |
| Vanguard Total Stock Market Index Fund | 3.08 |
| BlackRock Fund Advisors | 2.68 |
| Wellington Management Co. LLP | 2.57 |
| Vanguard 500 Index Fund | 2.33 |
| BlackRock Institutional Trust Co. NA | 2.23 |
| Capital Research & Management Co. (Global Investors) | 1.86 |
| Geode Capital Management LLC | 1.81 |
| Capital Research & Management Co. (International Investors) | 1.77 |
| JPMorgan Investment Management, Inc. | 1.43 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
UnitedHealth Management
| Name | Job |
|---|---|
| Stephen J. Hemsley | Chairman |
| Thomas Edward Roos | Chief Accounting Officer & Senior Vice President |
| Norman L. Wright | Chief Customer Experience Officer |
| Richard J. Mattera | Chief Development Officer & Senior Vice President |
| Sandeep Dadlani | Chief Digital & Technology Officer |
| Andrew Philip Witty | Chief Executive Officer & Director |
| Brian Thompson | Chief Executive Officer-UnitedHealthcare |
| Kevin Kandalaft | Chief Executive Officer-UnitedHealthcare-NM-Inc |
| John Franklin Rex | Chief Financial Officer & Executive Vice President |
| Stephanie L. Fehr | Chief Human Capital Officer & EVP-UnitedHealthcare |
| Rupert Mark Boden Bondy | Chief Legal Officer & Executive Vice President |
| Terry M. Clark | Chief Marketing Officer & Senior Vice President |
| Margaret-Mary Wilson | Chief Medical Officer & Executive Vice President |
| Erin L. McSweeney | Chief People Officer & Executive Vice President |
| Daniel J. Schumacher | Chief Strategy & Growth Officer |
| Patricia L. Lewis | Chief Sustainability Officer & Executive VP |
| D. Ellen Wilson | Executive Vice President |
| Richard J. Migliori | Executive Vice President |
| Todd Walthall | Executive Vice President-Enterprise Growth |
| Valerie C. Montgomery Rice | Independent Director |
| Paul R. Garcia | Independent Director |
| Timothy Patrick Flynn | Independent Director |
| John H. Noseworthy | Independent Director |
| Kristen L. Gil | Independent Director |
| Gail R. Wilensky | Independent Director |
| Frederick William McNabb | Independent Director |
| Frances Jacobs | Investor Relations Contact |
| Michele J. Hooper | Lead Independent Director |
| Dirk C. McMahon | President & Chief Operating Officer |
| Brett Manderfeld | Senior VP-Capital Markets Communications Area |
| Larry C. Renfro | Vice Chairman |
| Deedrea Grein | Vice President-Corporate Strategy |
| John Walthour | Vice President-Strategic Insights |